AGP
Artia Global Partners Portfolio holdings
AUM
$389M
This Quarter Return
+20.24%
1 Year Return
+34.68%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$290M
AUM Growth
+$290M
(+17%)
Cap. Flow
+$33.3M
Cap. Flow
% of AUM
11.48%
Top 10 Holdings %
Top 10 Hldgs %
66.21%
Holding
43
New
10
Increased
7
Reduced
4
Closed
8
Top Buys
| 1 |
IMGN
Immunogen Inc
IMGN
|
$10.3M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$9.38M |
| 3 |
Sarepta Therapeutics
SRPT
|
$8.84M |
| 4 |
89bio
ETNB
|
$8.82M |
| 5 |
Roivant Sciences
ROIV
|
$6.72M |
Top Sells
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$16.1M |
| 2 |
Biogen
BIIB
|
$7.9M |
| 3 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$6.28M |
| 4 |
Eli Lilly
LLY
|
$5.03M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$3.64M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Novo Nordisk
NVO
$251B
| $55.2M | 19.02% |
340,906
+19,851
| +6% | +$3.21M |
|
2
Merck
MRK
$210B
| $38M | 13.09% |
329,200
| – | – |
|
3
argenx
ARGX
$43.6B
| $18.1M | 6.24% |
46,438
+10,034
| +28% | +$3.91M |
|
|
4
Biogen
BIIB
$19.4B
| $14.9M | 5.13% |
52,275
-27,725
| -35% | -$7.9M |
|
5
AstraZeneca
AZN
$248B
| $13.7M | 4.71% |
190,752
+88,445
| +86% | +$6.33M |
|
6
AbbVie
ABBV
$372B
| $12.2M | 4.22% |
90,821
| – | – |
|
7
Moderna
MRNA
$9.37B
| $10.3M | 3.55% |
84,719
| – | – |
|
|
IMGN
8
DELISTED
Immunogen Inc
IMGN
| $10.3M | 3.53% |
+543,358
| New | +$10.3M |
|
|
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
| $9.85M | 3.4% |
51,175
| – | – |
|
|
ISEE
10
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $9.63M | 3.32% |
244,861
-159,754
| -39% | -$6.28M |
|
|
11
Apellis Pharmaceuticals
APLS
$3.48B
| $9.38M | 3.23% |
+102,940
| New | +$9.38M |
|
|
12
Sarepta Therapeutics
SRPT
$1.78B
| $8.84M | 3.05% |
+77,162
| New | +$8.84M |
|
|
13
89bio
ETNB
$1.34B
| $8.82M | 3.04% |
+465,465
| New | +$8.82M |
|
|
14
Roivant Sciences
ROIV
$8.15B
| $8.31M | 2.86% |
824,363
+666,600
| +423% | +$6.72M |
|
|
15
Eli Lilly
LLY
$657B
| $7.59M | 2.62% |
16,193
-10,735
| -40% | -$5.03M |
|
16
BioMarin Pharmaceuticals
BMRN
$11.2B
| $6.8M | 2.34% |
78,465
-40,000
| -34% | -$3.47M |
|
17
Vertex Pharmaceuticals
VRTX
$100B
| $6.44M | 2.22% |
18,314
+11,200
| +157% | +$3.94M |
|
18
Axsome Therapeutics
AXSM
$6.05B
| $6.31M | 2.18% |
+87,848
| New | +$6.31M |
|
19
Viking Therapeutics
VKTX
$3.04B
| $6.22M | 2.14% |
383,580
+315,172
| +461% | +$5.11M |
|
20
Neurocrine Biosciences
NBIX
$13.8B
| $4.24M | 1.46% |
45,000
| – | – |
|
21
BioNTech
BNTX
$24B
| $4.01M | 1.38% |
37,108
| – | – |
|
22
Protagonist Therapeutics
PTGX
$3.67B
| $3.1M | 1.07% |
+112,340
| New | +$3.1M |
|
23
Alnylam Pharmaceuticals
ALNY
$58.5B
| $3.03M | 1.05% |
15,971
| – | – |
|
24
Thermo Fisher Scientific
TMO
$186B
| $2.65M | 0.92% |
5,088
| – | – |
|
|
ITCI
25
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $2.63M | 0.91% |
41,600
| – | – |
|